CNTA Share Price Performance
US$39.76
28.49 (252.80%)
Price US$39.76
Share Pricen/a
Centessa Pharmaceuticals plc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
CNTA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Centessa Pharmaceuticals plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.28
- 100.00%
- -1,316.88%
- 20.9%
About CNTA
- Founded
- 2020
- Employees
- 114
- CEO
- WebsiteView website
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
